TB-500: The Seven-Amino-Acid Fragment With a Massive Reputation — and Zero Human Trials to Back It Up

TB-500 is one of the most widely used peptides in the self-experimentation community — and one of the least tested in humans. It is a synthetic heptapeptide corresponding to residues 17–23 of thymosin beta-4 (Tβ4), a 43-amino-acid protein that serves as one of the body’s primary actin-sequestering molecules. The fragment encompasses the actin-binding domain that researchers have identified as the active region responsible for cell migration and wound healing signaling.

The editorial challenge with TB-500 is a case of mistaken identity at industrial scale. Online forums, vendor sites, and even some clinician-facing materials routinely conflate TB-500 with its parent molecule. They cite clinical trials conducted with full-length thymosin beta-4 — Phase II/III ophthalmic trials, cardiac studies, IV safety data — as if those results apply to a seven-amino-acid fragment with different molecular weight, different three-dimensional structure, and different pharmacokinetics. They do not. Tβ4 is at Evidence Tier 3 with real human data. TB-500 is at Tier 4 with zero controlled human trials. This article explains why that distinction matters and what it means for anyone considering this compound.

TB-500 also carries an unresolved safety question that the community rarely discusses: the parent protein is overexpressed in several human cancers, and the same pro-angiogenic mechanism that makes it interesting for wound healing is the mechanism that raises oncological concerns. This article addresses that question directly, because the Dutch Uncle doesn’t skip the uncomfortable parts.

Quick Facts: TB-500 at a Glance

What Is TB-500?

Every cell in your body is a construction site. Actin — the protein that builds the internal scaffolding cells use to move, divide, and hold their shape — is the most abundant structural protein in those cells. And thymosin beta-4 is the foreman who controls the supply of raw actin materials. When tissue is damaged, cells at the wound edge need to move fast, build new blood vessels, and organize the repair. Tβ4 makes that possible by managing actin availability at exactly the moment the body demands it most.

TB-500 is a seven-amino-acid synthetic peptide copied from the region of thymosin beta-4 that researchers identified as the actin-binding active site — specifically, residues 17 through 23 of the 43-amino-acid parent protein. Its sequence is Ac-LKKTETQ, with an acetyl group added to the N-terminus for stability. The idea behind TB-500 is straightforward: isolate the active region that drives cell migration and tissue repair, synthesize it, and deliver it as a standalone molecule.

The name “TB-500” originated in equine veterinary contexts. Before the biohacking community adopted it, TB-500 was marketed as a performance-enhancing compound for racehorses. Australian and international anti-doping laboratories developed detection methods for it in equine urine and plasma in the early 2010s (PMID: 23084823), and a 2012 study confirmed the identity and characterization of the acetylated 17–23 fragment found in commercial TB-500 products (PMID: 22962027). The peptide migrated from the stable to the gym to the self-injection community, accumulating claims along the way — most of which cite research conducted on the parent molecule, not the fragment.

At 843 daltons, TB-500 is roughly one-sixth the molecular weight of full-length thymosin beta-4 (4,921 Da). It retains the actin-binding domain but lacks the remaining 36 amino acids that constitute the rest of the protein — amino acids that contribute to Tβ4’s three-dimensional folding, receptor interactions, and full signaling repertoire. Whether the fragment alone retains sufficient biological activity to replicate the parent molecule’s effects in a living human body is the central unanswered question. The animal data says yes, broadly. The human data says nothing — because no one has conducted the trial.

TB-500 vs. Thymosin Beta-4: The Distinction That Changes Everything

This is the most important section in this article. If you read nothing else, read this.

The biohacking community treats TB-500 and thymosin beta-4 as interchangeable names for the same thing. They are not. TB-500 is a fragment — seven amino acids out of forty-three. The distinction matters because the evidence base is completely different for each molecule.

What Full-Length Thymosin Beta-4 (Tβ4) Has

Phase II and Phase III clinical trials in humans for dry eye and corneal healing (RGN-259). Phase I IV safety studies in healthy volunteers showing tolerability up to 1,260 mg (PMID: 20536472). A 2016 pilot study of Tβ4-pretreated stem cell transplantation in heart attack patients (PMID: 27288307). A 2025 randomized, placebo-controlled cardiac trial in 96 patients. A Phase I safety study in healthy Chinese volunteers (PMID: 34346165).

What TB-500 (the Fragment) Has

Extensive preclinical data, almost entirely from studies that used the full-length parent protein, not the fragment. A 2024 rat pharmacokinetic and cytotoxicity study that is the most fragment-specific published research to date (PMID: 38382158). A 2012 doping detection study characterizing its identity in equine samples (PMID: 22962027). Zero controlled human trials. Zero Phase I safety data in humans. Zero published human pharmacokinetic data.

The analogy is imperfect, but consider this: a 43-word sentence conveys meaning you cannot reliably reconstruct from a 7-word excerpt, even if those 7 words happen to contain the verb. Full-length Tβ4 retains structural features — its complete three-dimensional folding, its full set of binding domains, its interaction surfaces with multiple downstream partners — that the truncated fragment simply does not possess. Whether those additional features matter for therapeutic effect is an open empirical question. It is not an open factual question whether studies on one molecule can be cited as evidence for the other: they cannot.

When someone online posts “TB-500 has been shown in clinical trials to heal [x],” check the citation. It will almost certainly reference a study that used full-length thymosin beta-4, not the Ac-LKKTETQ fragment. This is not a minor distinction. Pharmacology is not a synonym game.

Origins and Discovery

The history of TB-500 is inseparable from the history of thymosin research — but the path from thymus extract to synthetic fragment is more convoluted than most sources acknowledge.

In the late 1960s, Allan Goldstein’s laboratory at the Albert Einstein College of Medicine (later at George Washington University) isolated a crude extract from calf thymus glands called “Thymosin Fraction 5.” The extract contained dozens of peptides, and the lab systematically purified and named them — thymosin alpha-1, thymosin beta-1 through beta-15, and so on. The naming convention was alphabetical by isoelectric point, and it created a misleading impression that these molecules were functionally related. They are not. Thymosin alpha-1 became an approved drug for hepatitis B (Zadaxin). Thymosin beta-4 turned out to be an actin-sequestering protein with almost nothing to do with immune function per se.

Tβ4 was first identified and sequenced in 1981 (PMID: 6893036). Its actin-binding function was characterized in the 1990s. The critical discovery came in 1999 when Malinda and colleagues demonstrated that exogenous Tβ4 accelerated wound healing in rats (PMID: 10469335) — re-epithelialization increased by 42–61% over controls, with enhanced angiogenesis and collagen deposition. This paper launched the translational research program that eventually produced the RGN-259 clinical trials.

TB-500 as a commercial product emerged from a different track entirely. Veterinary applications — particularly in horse racing — drove demand for a synthetic version of Tβ4’s active region. The 17–23 fragment (Ac-LKKTETQ) was identified as the minimal peptide sequence sufficient for actin binding and cell migration stimulation. By the late 2000s, TB-500 was being marketed to equine trainers and then, rapidly, to human self-experimenters. The doping control community responded: Scarth et al. (2012, PMID: 23084823) developed the first LC-MS method for detecting TB-500 and its metabolites in horse urine and plasma, and Deleris et al. (2012, PMID: 22962027) confirmed the chemical identity of commercial TB-500 products.

The jump from horse barn to bodybuilding forum happened without any human clinical validation. TB-500 entered the biohacking pharmacopoeia on the strength of animal data generated for the parent molecule. It remains there today — widely used, widely discussed, and entirely untested in a controlled human trial.

Mechanism of Action

TB-500’s mechanism derives from the actin-binding domain of its parent molecule, thymosin beta-4. Understanding what TB-500 does requires understanding what actin dynamics mean for tissue repair — and then asking the honest question of whether a seven-amino-acid fragment reproduces those effects.

Actin Sequestration and Cell Migration

Actin is the most abundant protein in eukaryotic cells. It exists in two forms: monomeric G-actin (globular, soluble) and polymerized F-actin (filamentous, structural). The balance between these forms determines whether a cell holds still or moves. Tβ4 binds G-actin in a 1:1 complex, creating an intracellular reservoir of available building material that cells can deploy rapidly when they need to migrate — into a wound, toward a site of inflammation, or along a newly forming blood vessel.

The TB-500 sequence (residues 17–23) includes the central actin-binding motif of Tβ4. In vitro, this fragment promotes cell migration in a manner similar to the parent protein. Whether it achieves the same magnitude of effect in vivo — where the full protein’s additional domains, folding, and receptor interactions contribute — is not established by the available evidence.

Angiogenesis (New Blood Vessel Formation)

The 17–23 region of Tβ4 is specifically implicated in angiogenesis — the growth of new blood vessels from existing vasculature. In vitro, endothelial cells treated with Tβ4 or its active fragments show increased tube formation. In vivo (rodent models), exogenous Tβ4 administration increases capillary density in ischemic and infarcted tissue. The actin-binding domain promotes endothelial cell migration and organization into vascular structures.

This is the mechanism that makes TB-500 interesting for injury recovery: new blood vessels mean more oxygen and nutrient delivery to damaged tissue, faster removal of metabolic waste, and better cellular access for repair. It is also the mechanism that raises the cancer question — because tumors use angiogenesis to feed their growth. More on that in the Safety section.

Anti-Inflammatory Signaling

Tβ4 suppresses NF-κB — a master transcription factor that drives the inflammatory cascade. In animal models, Tβ4 reduces circulating levels of pro-inflammatory cytokines including TNF-α, IL-1β, and IL-6. In corneal injury models, it decreased inflammatory markers MIP-1α and MCP-1.

The relevance to TB-500 specifically: the anti-inflammatory effects of Tβ4 appear to involve multiple domains of the protein, not exclusively the 17–23 fragment. The N-terminal region (amino acids 1–15) has been specifically identified as mediating anti-inflammatory and anti-fibrotic effects, while residues 1–4 (the Ac-SDKP tetrapeptide) have their own independent anti-inflammatory pathway. It is possible that TB-500 retains some anti-inflammatory activity through the actin-binding domain, but the strongest anti-inflammatory evidence points to parts of the protein that TB-500 does not contain.

Anti-Fibrotic Effects (The Ac-SDKP Connection)

Ac-SDKP (N-acetyl-seryl-aspartyl-lysyl-proline) is a tetrapeptide derived from the N-terminal region of Tβ4 (residues 1–4) — a completely different fragment from TB-500 (residues 17–23). Ac-SDKP has a substantial independent research body demonstrating anti-fibrotic effects in cardiac and renal models: it reverses cardiac fibrosis dose-dependently in rats with renovascular hypertension (PMC6824434), attenuates renal inflammation and fibrosis, inhibits TGF-β–mediated fibrotic signaling in human mesangial cells, and is degraded by ACE — meaning that ACE inhibitors increase endogenous Ac-SDKP levels in humans (PMID: 26656271 — systematic review, 3 studies, 106 participants).

The Ac-SDKP data is sometimes cited in TB-500 discussions as if the two fragments are interchangeable. They are not. Ac-SDKP is residues 1–4. TB-500 is residues 17–23. They are different molecules cleaved from different regions of the same parent protein, with different downstream effects. TB-500 may have anti-fibrotic properties through its actin-modulating mechanism, but the specific anti-fibrotic evidence belongs to Ac-SDKP, not TB-500.

Hair Growth

Multiple rodent studies have demonstrated that Tβ4 promotes hair follicle development and accelerates hair growth. Philp et al. (2003, PMID: 14657002) showed that Tβ4 activates hair follicle stem cells in mice. Follow-up studies confirmed the mechanism: Tβ4 promotes migration and differentiation of follicle stem cell progenitors through Wnt/β-catenin signaling, with upregulation of Lef-1, MMP-2, and VEGF (PMID: 33393222). Exogenous Tβ4 increased the rate of hair growth in normal mice and promoted secondary follicle development in cashmere goats.

These studies used full-length Tβ4, not TB-500. Whether the 17–23 fragment alone is sufficient to reproduce the hair growth effect has not been directly tested in a published study. The stem cell migration mechanism is plausible given TB-500’s actin-binding function, but the evidence is extrapolated, not demonstrated.

Key Research Areas and Studies

Wound Healing (Preclinical — All Tβ4, Not TB-500)

The foundational wound healing evidence comes from the full-length parent protein. Malinda et al. (1999, PMID: 10469335) showed that topical or IP Tβ4 increased re-epithelialization by 42% at 4 days and 61% at 7 days in rat full-thickness punch wounds, with increased collagen deposition and angiogenesis. Goldstein et al. (2012, PMID: 23050815) confirmed accelerated dermal healing across multiple animal models and referenced two Phase II clinical trials in stasis and pressure ulcers (full Tβ4, not TB-500) showing healing acceleration by approximately one month. Ehrlich and Hazard (2010, PMID: 20536458) found that incisional wounds in rats treated with Tβ4 healed with minimal scarring and without loss of wound breaking strength.

Tendon and Ligament Repair (Preclinical — Tβ4)

Ehrlich and Hazard (2013, PMID: 23523891) delivered Tβ4 in fibrin sealant to enhance rat medial collateral ligament repair. The treatment group showed uniform, evenly spaced fiber bundles with significantly increased collagen fibril diameters. This is one of the few studies directly addressing the musculoskeletal injury application that drives most community interest in TB-500.

Cardiac Repair (Preclinical — Tβ4)

Bock-Marquette et al. (2010, PMID: 20536454) established Tβ4 as the first known molecule to simultaneously inhibit cardiomyocyte death, stimulate angiogenesis, and activate endogenous cardiac progenitor cells after systemic administration. Smart et al. (2012, PMID: 23050819) showed Tβ4 promotes myocardial survival under hypoxia and promotes neoangiogenesis for cardiac repair. Important clarification: Tβ4 does NOT reprogram epicardial cells into cardiomyocytes as initially hypothesized. Benefit operates through progenitor activation and angiogenesis, not direct muscle regeneration.

Neurological Injury (Preclinical — Tβ4)

Xiong et al. (2012, PMID: 23050817) found that Tβ4 after TBI in rats reduced cortical lesion volume by 20–30%, reduced hippocampal cell loss, and improved sensorimotor functional recovery. In a second study (PMID: 22324420), Tβ4 initiated 6 hours post-TBI improved spatial learning and enhanced neurogenesis in the injured hippocampus, establishing a clinically relevant delayed-treatment window. Chopp and Zhang (2015, PMID: 24937047) showed improved behavioral outcomes and increased surviving neurons and oligodendrocytes after spinal cord injury in rats.

Muscle Regeneration (Preclinical — Tβ4)

Tokura et al. (2011, PMID: 20880960) demonstrated that muscle injury–induced Tβ4 acts as a chemoattractant for myoblasts, with mRNA levels upregulated in early-stage regenerating muscle fibers. Both Tβ4 and its sulfoxidized form accelerated wound closure and increased chemotaxis of myoblastic cells.

TB-500-Specific Research (The Fragment Itself)

Ahmad et al. (2024, PMID: 38382158) is the most fragment-specific published study. It quantified TB-500 and its metabolites in in-vitro experiments and rats, found no cytotoxicity, and identified Ac-LK as the primary metabolite (0–6 h) and Ac-LKK as a long-term metabolite (detectable up to 72 h). Deleris et al. (2012, PMID: 22962027) synthesized and characterized the acetylated 17–23 fragment, confirming the chemical identity of commercial TB-500 products. Scarth et al. (2012, PMID: 23084823) developed the first detection method for TB-500 and its metabolites in equine biological samples.

The Human Evidence Landscape

There are zero published controlled human trials for TB-500.

This section exists because Peptidings treats the absence of human evidence as a finding, not a gap to gloss over. For a compound as widely used as TB-500, the complete absence of human data is itself an important data point.

The parent molecule — full-length thymosin beta-4 — has human data: multiple Phase II/III ophthalmic trials (RGN-259) for dry eye and neurotrophic keratopathy, Phase I IV safety studies in healthy volunteers (PMID: 20536472; PMID: 34346165), a 2016 pilot cardiac study (PMID: 27288307), and a 2025 randomized cardiac trial in 96 patients. None of these trials tested TB-500. All used the full 43-amino-acid protein. The routes studied (topical ophthalmic drops, intravenous infusion) are not the route used by the self-experimentation community (subcutaneous injection).

What this means in practice: When community members say “TB-500 has been tested in humans,” they are conflating two different molecules. When vendors claim “clinical trial evidence,” they are citing studies of a different compound. When clinician-facing materials reference “thymosin beta-4 clinical data” in the context of TB-500, they are committing the same conflation. The editorial position of Peptidings is simple: the evidence for one molecule is not evidence for a different molecule, regardless of structural relationship.

Comparison to cluster peers: Within the Injury Recovery cluster, BPC-157 (Tier 3) has at least three small human studies — two for IBD and one for fracture healing. GHK-Cu (Tier ~) has topical human data. Thymosin Beta-4 (Tier 3) has multiple Phase II/III trials. TB-500, despite being among the most popular compounds in the cluster, has the thinnest human evidence of any — literally none.

Common Claims vs. Current Evidence

CLAIM	WHAT THE EVIDENCE SHOWS	VERDICT
TB-500 heals tendon and ligament injuries	Full-length Tβ4 enhanced MCL repair in rats (PMID: 23523891). TB-500 fragment has not been tested for tendon/ligament healing in any published study. No human data for either molecule in this indication.	Preclinical Only
TB-500 speeds wound healing	Tβ4 accelerated wound healing by 42–61% in multiple rodent models (PMID: 10469335). Two Phase II trials of full Tβ4 in stasis/pressure ulcers showed acceleration. Fragment not directly tested.	Preclinical Only
TB-500 reduces inflammation	Tβ4 suppresses NF-κB and reduces TNF-α, IL-1β, IL-6 in animal models. Anti-inflammatory activity involves multiple protein domains, including N-terminal regions TB-500 does not contain.	Preclinical Only
TB-500 grows new blood vessels (angiogenesis)	The 17–23 region IS specifically implicated in angiogenesis. Endothelial tube formation confirmed in vitro. Capillary density increased in rodent models with full Tβ4. Most directly relevant claim — but still no human data.	Preclinical Only
TB-500 repairs cardiac tissue	Tβ4 shows robust cardiac repair in animal models — reduced infarct size, increased vessel density, progenitor cell activation. Human cardiac trials use full-length IV Tβ4, not SC fragment.	Preclinical Only
TB-500 promotes hair regrowth	Tβ4 activates hair follicle stem cells and accelerates hair growth in mice (PMID: 14657002). Mechanism involves Wnt/β-catenin signaling. All studies used full-length protein.	Preclinical Only
TB-500 helps with brain and spinal cord injuries	Tβ4 reduced cortical lesion volume by 20–30% and improved functional recovery after TBI in rats (PMID: 23050817). SCI outcomes also improved. No human neurological data for either molecule.	Preclinical Only
TB-500 is the same as thymosin beta-4	TB-500 is a 7-amino-acid fragment (843 Da) of the 43-amino-acid parent protein (4,921 Da). Different MW, different structure, different PK, different evidence base. Categorically false.	Unsupported
TB-500 has been tested in clinical trials	Zero controlled human trials for TB-500. All cited trials used full-length Tβ4 (RGN-259, cardiac studies). The fragment has never been administered to humans in a published clinical study.	Unsupported
TB-500 is safe because it’s a natural peptide	TB-500 is synthetic. The parent protein Tβ4 is endogenous. No human safety data exists for TB-500. 2024 rat study found no cytotoxicity (PMID: 38382158), but absence of toxicity in rats ≠ safety data in humans.	Mixed Evidence
TB-500 + BPC-157 is a proven healing stack	No published study has evaluated this combination. Both compounds are popular in the self-experimentation community, but the “stack” is entirely community-derived with zero published validation.	Unsupported
TB-500 reduces scarring and fibrosis	The anti-fibrotic data is strongest for Ac-SDKP (Tβ4 residues 1–4), a DIFFERENT fragment. Tβ4 reduced myofibroblast appearance in wound models (PMID: 20536458). TB-500 may have some anti-fibrotic effect through actin modulation, but the specific evidence belongs to a different molecule.	Mixed Evidence

We currently don’t have any vetted partners for this compound. Check back soon.

Safety, Risks, and Limitations

The Cancer Question

This is the most serious safety consideration for TB-500, and it is rarely discussed in community forums or vendor materials. The Dutch Uncle discusses it.

Thymosin beta-4 is overexpressed in several human cancers. In pancreatic cancer cells, Tβ4 stimulates proinflammatory cytokine secretion (IL-6, IL-8, MCP-1) and JNK activation (PMC2930015). Tβ4 regulates colon cancer cell migration via Ku80 interaction (PMID: 20536451), and targeting Tβ4 impairs tumorigenic activity of colon cancer stem cells (PMID: 20566622). Tβ4 silencing suppresses proliferation and invasion of non-small cell lung cancer cells via the Notch1 pathway (PMID: 27521796). Upregulation of Tβ4 in weakly tumorigenic cells converted them to develop tumors and form lung metastases in mice.

The counterpoint: In multiple myeloma, Tβ4 has TUMOR SUPPRESSIVE effects (PMC2805724). Decreased Tβ4 expression correlates with poor prognosis. Overexpression decreases proliferation and increases apoptosis sensitivity. Mice injected with Tβ4-overexpressing myeloma cells survived longer.

The net assessment: The relationship between Tβ4 and cancer is genuinely complex and context-dependent — pro-tumorigenic in some solid cancers, tumor-suppressive in at least one hematological malignancy. The pro-angiogenic mechanism that makes Tβ4 (and potentially TB-500) interesting for wound healing is precisely the mechanism that raises oncological concerns. New blood vessels are useful for healing. They are also useful for feeding tumors.

No study has directly examined whether exogenous TB-500 administration promotes tumor growth in animals with pre-existing cancers. This is a data gap, not an established risk — but it is a data gap that should give pause to anyone with undiagnosed malignancies or a significant cancer history.

No Human Safety Data for TB-500

Zero Phase I safety studies have been conducted for TB-500 in humans. The 2024 rat study (PMID: 38382158) found no cytotoxicity, which is a basic and necessary finding — but a negative toxicity screen in rats is the absolute minimum bar and does not constitute a human safety profile. Full-length Tβ4 has human safety data from Phase I IV studies showing tolerability up to 1,260 mg (PMID: 20536472), but those studies used a different molecule via a different route.

Community-Reported Side Effects

Anecdotal reports from self-experimentation forums describe injection site redness, swelling, and irritation; temporary fatigue and lethargy (loading phase); headache; and nausea (less common). These reports carry zero evidentiary weight — they are uncontrolled observations from individuals using unregulated products of variable purity, frequently in combination with other compounds.

Purity and Contamination Risk

TB-500 is sold as a “research chemical” without pharmaceutical-grade manufacturing oversight. The absence of FDA regulation means no guaranteed purity, potency, sterility, or identity verification. A 2022 study by Barroso et al. (PMID: 36482504) specifically examined TB-500/TB-1000 products and found issues with misbranding and adulteration. Certificate of Analysis (CoA) from third-party testing is the only partial mitigation — and even CoAs vary wildly in rigor. (See: How to Read a Certificate of Analysis)

Unknown Pharmacokinetics in Humans

No human PK data exists for TB-500. The 2024 rat study identified metabolites (Ac-LK at 0–6 h, Ac-LKK at up to 72 h), but rat metabolism does not reliably predict human metabolism. Half-life, bioavailability, tissue distribution, and elimination pathways are all unknown in humans. Community dosing protocols are, by definition, shots in the dark.

Legal and Regulatory Status

FDA Status

TB-500 is not approved for any therapeutic indication in humans or animals. Thymosin beta-4 is classified as a Category 2 bulk drug substance by the FDA, meaning it is restricted from use by compounding pharmacies. Unlike several other peptides (Thymosin Alpha-1, CJC-1295, Ipamorelin) that were removed from Category 2 in September 2024 following PCAC review, thymosin beta-4 and its fragments remain on Category 2. The February 2026 HHS announcement regarding peptide regulation may affect future availability, but as of this writing, Category 2 status is in effect.

TB-500 is available from research chemical vendors and gray-market peptide suppliers. It is sold labeled “for research purposes only” — a legal fiction that thinly veils human self-administration.

WADA Status

Prohibited at all times. Listed under S2.3 (Growth Factors and Growth Factor Modulators) since 2018 as a non-Specified Substance. The prohibition applies to both full-length thymosin beta-4 and all of its derivatives and fragments, explicitly including TB-500. WADA has funded development of detection methodologies for TB-500 in both equine and human biological matrices. Any competitive athlete who tests positive for TB-500 faces a potential four-year ban under the World Anti-Doping Code.

International Status

No country has approved TB-500 for therapeutic use. It is not a scheduled controlled substance in most jurisdictions but occupies a gray legal area — not approved, not specifically banned for possession, but prohibited in competitive sport and restricted from compounding.

Dosing in Published Research

There is no published human dosing data for TB-500. This section exists to state that clearly and to prevent the common misconception that community protocols have any basis in published research.

For the parent molecule (full-length Tβ4), published human dosing includes:

STUDY	DOSE / ROUTE	NOTES
Phase I IV Safety (PMID: 20536472)	42–1,260 mg IV, single and multiple doses over 14 days	Healthy volunteers. Full-length Tβ4, not TB-500.
Ophthalmic (RGN-259)	0.1% Tβ4 solution, topical eye drops	Phase II/III. Full-length Tβ4.
Cardiac pilot (PMID: 27288307)	Tβ4-pretreated EPCs, not direct Tβ4 dosing	Proof-of-concept. Not a dose-finding study.

Dosing in Self-Experimentation Communities

PROTOCOL PARAMETER	TYPICAL COMMUNITY RANGE	NOTES
Loading Phase Dose	2–2.5 mg twice per week	4–6 weeks. Total: 4–5 mg/week
Alternative Loading	5–10 mg/week split 2–3 injections	Higher-dose approach, less common
Maintenance Dose	2 mg once every 1–2 weeks	Duration varies; many cycle indefinitely
Route	Subcutaneous (abdomen, outer thigh)	Some IM reports; SC is dominant
Reconstitution	Bacteriostatic water	Standard lyophilized peptide prep (see /guides/reconstitution/)
Storage	2–8°C reconstituted; room temp lyophilized	Standard peptide storage (see /guides/storage/)
Common Stack	BPC-157 (250–500 mcg/day) + TB-500	Zero published evidence for this combination
Cycling	4–6 week loading → maintenance or time off	No pharmacological basis published

These dosing ranges derive from veterinary extrapolation (equine TB-500 use in horse racing), forum consensus (Reddit r/peptides, bodybuilding forums), anecdotal dose-response reports from self-experimenters, and vendor recommendations (conflict of interest: they profit from sales). No published study supports any of these protocols.

Frequently Asked Questions

Related Compounds: How TB-500 Compares

TB-500 sits within a cluster of tissue repair compounds, each with a different evidence profile and mechanism of action. The comparison illuminates why evidence tier matters — and why assuming equivalence between compounds that “all help with healing” misses critical pharmacological distinctions.

Thymosin Beta-4 (Tβ4): The parent molecule. 43 amino acids vs. TB-500’s 7. Tier 3 (Pilot / Limited Human Data) with Phase II/III ophthalmic trials and Phase I/II cardiac data. TB-500 is a fragment of Tβ4 and cannot inherit its clinical evidence. The community conflates them; the pharmacology does not support that conflation.

BPC-157: Synthetic pentadecapeptide fragment of gastric protein BPC. Tier 3 with three small human studies (two IBD, one fracture). Like TB-500, it is a fragment of a larger endogenous protein marketed for tissue repair. Unlike TB-500, it has at least minimal human data. The BPC-157 + TB-500 stack is popular but unstudied.

GHK-Cu: Tripeptide + copper. Tier ~ (It’s Complicated) — route-dependent evidence. Topical human data exists; injectable evidence is limited. Like TB-500, the community uses it for tissue repair, but the mechanism (copper-dependent signaling, collagen synthesis) is completely different from actin-mediated cell migration.

KPV: C-terminal tripeptide of alpha-MSH. Tier 4 (Preclinical Only). Anti-inflammatory through MC1R agonism — a different pathway than TB-500’s actin-based mechanism. Both are short synthetic fragments with zero human trials.

KGF / Palifermin: FDA-approved (Tier 1) growth factor for oral mucositis. Demonstrates what full regulatory development looks like for a tissue repair peptide — the endpoint TB-500 has never approached.

Compound	Type	Primary Target	Half-Life	FDA Status	WADA Status	Evidence Tier	Primary Tissue Target	Route	Human Evidence Status	Key Differentiator
BPC-157	Synthetic pentadecapeptide (15 amino acids, derived from gastric protective protein BPC)	VEGF / Nitric oxide (proposed multi-target)	~2–6 hours	Not FDA-approved	Prohibited — S0 (Non-Approved Substances)	Tier 3 — Pilot / Limited Human Data	Musculoskeletal, tendon, ligament, GI tract, CNS	Subcutaneous injection + Oral (both routes studied)	3 published human pilot studies (~30 subjects combined); no RCTs	Broadest tissue tropism in cluster. Only injury-repair peptide with both oral and injectable evidence. Most evidence in rodent models
TB-500	Synthetic 4-amino-acid fragment (residues 17–23 of Thymosin Beta-4)	Actin binding (cell migration, angiogenesis)	~2–3 hours	Not FDA-approved	Prohibited — S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics)	Tier 4 — Preclinical Only	Musculoskeletal (muscle, tendon, ligament), cardiac, neurological	Subcutaneous injection	Zero published human clinical trials; animal models and cell culture only	Smallest fragment studied; synthetic derivative of endogenous Thymosin Beta-4. Actin sequestration may drive cell migration
Thymosin Beta-4	Endogenous 43-amino-acid peptide (ubiquitous actin-sequestering protein)	Actin binding, cell migration, angiogenesis	~2–4 hours	Not FDA-approved	Prohibited — S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics)	Tier 3 — Pilot / Limited Human Data	Broad: muscle, cardiac, neurological, immune, epithelial	Subcutaneous injection + Topical (cosmetics)	Few human studies; cardiac regeneration in early-stage human data; cosmetic formulations	Full-length parent peptide of TB-500. Endogenous compound; ubiquitous in mammalian tissues. More potent than TB-500 fragment in vitro
GHK-Cu	Synthetic tripeptide-copper complex (Gly-His-Lys chelated to Cu2+)	Collagen synthesis, wound healing, TGF-beta modulation	~2 hours topical; ~4–6 hours systemic (estimated)	Not FDA-approved (topical in cosmetics; injectable investigational)	Prohibited — S0 (injectable as growth factor analog); topical unregulated	Tier 5 — It's Complicated	Dermal (collagen, elastin remodeling); broad systemic effects proposed but unverified	Topical (cosmetics — extensive evidence) vs. Subcutaneous injection (preclinical only)	Topical: 30+ years cosmetic use data; Injectable: zero human trials	Route-dependent evidence: topical skin rejuvenation well-established, but injectable claims extrapolate from fundamentally different delivery
AHK-Cu	Synthetic copper tripeptide variant (Ala-His-Lys chelated to Cu2+)	Copper chelation, extracellular matrix remodeling, growth factor signaling	~2–4 hours (estimated)	Not FDA-approved	Not WADA-listed	Tier 4 — Preclinical Only	Dermal (hair follicle, scalp), cosmetic	Topical (cosmetics)	No human clinical trials; in vitro and cosmetic formulation data only	GHK-Cu structural analog with alanine substitution. Primarily studied for hair growth. Less evidence base than GHK-Cu
LL-37	Human cathelicidin antimicrobial peptide (37 amino acids)	Antimicrobial, wound healing, angiogenesis, vitamin D-regulated immune modulation	~2–4 hours	Not FDA-approved	Not WADA-listed	Tier 3 — Pilot / Limited Human Data	Skin, mucosal surfaces, immune system	Subcutaneous injection, Topical	Limited human data; antimicrobial efficacy well-characterized in vitro; wound healing in animal models	Endogenous host defense peptide. Dual role: direct antimicrobial activity + immune modulation. Vitamin D pathway regulates expression
KPV	Alpha-MSH C-terminal tripeptide (Lys-Pro-Val)	NF-kB inhibition, anti-inflammatory (no melanocortin receptor activation)	~1–2 hours (estimated)	Not FDA-approved	Not WADA-listed	Tier 4 — Preclinical Only	GI tract (colitis models), skin, immune system	Subcutaneous injection, Oral (investigational)	No published human clinical trials; animal models (colitis, dermatitis) only	Smallest anti-inflammatory peptide in cluster (3 amino acids). NF-kB pathway without melanocortin receptor binding. GI-focused research
VIP	Endogenous 28-amino-acid neuropeptide (vasoactive intestinal peptide)	VPAC1/VPAC2 receptor agonism; vasodilation, immunomodulation, bronchodilation	~1–2 minutes (extremely short)	Not FDA-approved (aviptadil in clinical trials)	Not WADA-listed	Tier 2 — Clinical Trials	Pulmonary, GI tract, immune system, neurological	Subcutaneous injection, IV infusion, Intranasal	Multiple Phase 2 trials (ARDS, pulmonary hypertension, sarcoidosis); aviptadil in FDA pipeline	Shortest half-life in cluster. CIRS protocol use. Aviptadil (synthetic VIP) is furthest along FDA pathway among non-approved compounds here
KGF / Palifermin	Recombinant keratinocyte growth factor (FGF-7)	FGFR2b receptor; keratinocyte proliferation, epithelial barrier repair	~3–5 hours	FDA-approved (Kepivance for oral mucositis)	Not WADA-listed	Tier 1 — Approved Drug	Epithelial surfaces (oral mucosa, GI tract, skin)	Intravenous injection (FDA-approved route)	FDA-approved for chemo-induced oral mucositis; multiple Phase 2/3 trials	Only FDA-approved compound in Cluster B. Specific to epithelial tissues. IV-only approved route limits off-label accessibility
Substance P	Endogenous 11-amino-acid tachykinin neuropeptide	NK1 receptor agonism; fibroblast migration, angiogenesis, immune activation	~1–2 minutes	Not FDA-approved	Not WADA-listed	Tier 3 — Pilot / Limited Human Data	Corneal epithelium, skin, nervous system	Topical (corneal), Subcutaneous injection	Human data primarily in corneal wound healing; limited systemic human studies	Endogenous pain signaling peptide repurposed for tissue repair. Strongest human evidence in corneal healing. Dual role: nociception + repair
PRP	Autologous platelet-rich plasma (concentrated growth factor preparation)	PDGF, VEGF, TGF-beta release via platelet degranulation	N/A (not a single molecule)	FDA-cleared devices (not drug-approved)	Prohibited — M1 (Manipulation of Blood and Blood Components)	Tier 2 — Clinical Trials	Musculoskeletal (tendon, cartilage, bone), dermal, hair	Injection (local to injury site)	Hundreds of RCTs across orthopedic, dermatologic, and dental applications	Non-peptide. Autologous preparation — no synthetic manufacturing. Largest clinical evidence base in cluster but high study heterogeneity
ARA-290	Synthetic 11-amino-acid peptide (cibinetide; EPO-derived tissue-protective peptide)	Innate Repair Receptor (EPOR/CD131 heterodimer) selective agonist	~2–4 hours	Not FDA-approved (Phase 2b completed)	Not WADA-listed	Tier 2 — Clinical Trials	Peripheral nerves, retina, cardiac, immune system	Subcutaneous injection (1–8 mg daily in trials); IV infusion (early trials)	Phase 2b complete (sarcoidosis SFN — DOSARA trial); Phase 2 (diabetic neuropathy, diabetic macular edema)	EPO-derived but does NOT bind classical EPO receptor. No erythropoietic activity. Tissue protection without blood doping risk. Furthest clinical development for neuropathy

Summary and Key Takeaways

TB-500 is a seven-amino-acid synthetic fragment of thymosin beta-4 that encompasses the actin-binding domain responsible for cell migration and tissue repair signaling. It is among the most widely used compounds in the peptide self-experimentation community, typically injected subcutaneously for tendon, ligament, and muscle injury recovery.

The evidence picture is defined by a single, overwhelming fact: TB-500 has zero published controlled human trials. Every claim made for TB-500 traces back to research conducted on the full-length parent protein — a different molecule with a different weight, different structure, and different pharmacokinetics. The preclinical data for Tβ4 is impressive: accelerated wound healing across multiple animal models, cardiac repair including reduced infarct size and enhanced angiogenesis, neuroprotection after traumatic brain and spinal cord injury, and hair follicle activation. But that data belongs to the parent, not the fragment.

The cancer question compounds the uncertainty. Tβ4 is overexpressed in several human cancers, and its pro-angiogenic mechanism — the same mechanism that makes it interesting for healing — has been linked to tumor growth and metastasis in animal models. The relationship is complex (tumor-suppressive in myeloma), but the question is unresolved, and unresolved oncological questions deserve direct answers, not community handwaving.

Verdict Recapitulation

The mechanism is understood. The parent molecule has human data confirming biological activity. The preclinical portfolio is broad and consistent. But TB-500 itself is entirely untested in humans, the cancer question is real, and the community has run far ahead of the science. Use TB-500 with full awareness of what you know and what you don’t — and understand that for this compound, what you don’t know is almost everything.

Where to Source TB-500

Further Reading and Resources

If you want to go deeper on TB-500, the evidence landscape for tissue repair peptides, or the methodology behind how we evaluate this research, these are the places worth your time.

On Peptidings

• Thymosin Beta-4 — The parent molecule. Tier 3 (Pilot / Limited Human Data).
• BPC-157 — Cluster peer. Tier 3 with three small human studies.
• GHK-Cu — Cluster peer. Tier ~ (It’s Complicated).
• KPV — Cluster peer. Tier 4 (Preclinical Only).
• KGF / Palifermin — FDA-approved tissue repair. Tier 1.
• How to Reconstitute Lyophilized Peptides
• Subcutaneous Injection Technique Guide
• Peptide Storage and Handling Guide
• Evidence Levels Explained
• How to Read a Certificate of Analysis
• FDA and WADA Regulatory Status
• Half-Lives and Dosing Intervals

External Resources

• PubMed — Biomedical Research Database — Search for “TB-500” or “thymosin beta-4 fragment”.
• ClinicalTrials.gov — Check for registered or ongoing trials (note: results will show Tβ4 trials, not TB-500).

Selected References and Key Studies

• Malinda KM et al., "Thymosin beta4 accelerates wound healing." J Invest Dermatol, 1999;113(3):364-368. PubMed
• Goldstein AL et al., "The regenerative peptide thymosin β4 accelerates the rate of dermal healing in preclinical animal models and in patients." Ann N Y Acad Sci, 2012;1270:37-44. PubMed
• Ehrlich HP, Hazard SW III, "Thymosin beta4 enhances repair by organizing connective tissue and preventing the appearance of myofibroblasts." Ann N Y Acad Sci, 2010;1194:118-124. PubMed
• Ehrlich HP, Hazard SW III, "Thymosin β4 enhances the healing of medial collateral ligament injury in rat." J Orthop Res, 2013;31(7):1065-1071. PubMed
• Bock-Marquette I et al., "Thymosin beta4 and cardiac repair." Ann N Y Acad Sci, 2010;1194:87-96. PubMed
• Smart N et al., "Cardiac repair with thymosin β4 and cardiac reprogramming factors." Ann N Y Acad Sci, 2012;1270:66-72. PubMed
• Kleinman HK, Sosne G, "Cardioprotection by Thymosin Beta 4." Ann N Y Acad Sci, 2016;1369(1):9-17. PubMed
• Crockford D, "Development of thymosin beta4 for treatment of patients with ischemic heart disease." Ann N Y Acad Sci, 2007;1112:385-395. PubMed
• Xiong Y et al., "Neuroprotective and neurorestorative effects of thymosin beta4 treatment following experimental traumatic brain injury." Ann N Y Acad Sci, 2012;1270:51-58. PubMed
• Xiong Y et al., "Neuroprotective and neurorestorative effects of thymosin β4 treatment initiated 6 hours after traumatic brain injury in rats." J Neurosurg, 2012;116(5):1081-1092. PubMed
• Chopp M, Zhang ZG, "Beneficial effects of thymosin β4 on spinal cord injury in the rat." Neurosci Lett, 2015;586:1-5. PubMed
• Philp D et al., "Thymosin beta4 increases hair growth by activation of hair follicle stem cells." FASEB J, 2004;18(2):385-387. PubMed
• Philp D et al., "Thymosin beta 4 induces hair growth via stem cell migration and differentiation." Ann N Y Acad Sci, 2007;1112:95-103. PubMed
• Xiao R et al., "Multiple potential roles of thymosin β4 in the growth and development of hair follicles." Life Sci, 2021;267:118969. PubMed
• Shifei L et al., "The anti-inflammatory peptide Ac-SDKP: Synthesis, role in ACE inhibition, and its therapeutic potential in hypertension and cardiovascular diseases." Peptides, 2018;104:29-38. PubMed
• Tokura Y et al., "Muscle injury-induced thymosin β4 acts as a chemoattractant for myoblasts." J Biochem, 2011;149(1):43-48. PubMed
• Deleris G et al., "Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500." J Pharm Biomed Anal, 2012;70:601-605. PubMed
• Scarth JP et al., "Doping control analysis of TB-500, a synthetic version of an active region of thymosin β₄, in equine urine and plasma." Drug Test Anal, 2012;4(10):765-774. PubMed
• Ahmad S et al., "Simultaneous quantification of TB-500 and its metabolites in in-vitro experiments and rats by UHPLC-Q-Exactive orbitrap MS/MS." J Chromatogr B, 2024;1232:123972. PubMed
• Huff T et al., "Thymosin β4: a multi-functional regenerative peptide." Drug Discov Today, 2011;16(15-16):619-627. PubMed
• Wang Z et al., "Thymosin β4 silencing suppresses proliferation and invasion of non-small cell lung cancer cells by repressing Notch1 activation." Acta Biochim Biophys Sin, 2016;48(9):788-794. PubMed
• Sosne G et al., "Thymosin beta 4: a novel corneal wound healing and anti-inflammatory agent." Clin Ophthalmol, 2007;1(3):201-207. PMC2701135
• Barroso O et al., "TB500/TB1000 and SGF1000: A scientific approach for a better understanding of misbranded and adulterated drugs." Drug Test Anal, 2023;15(5):473-481. PubMed